Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Frazier Life Sciences has successfully closed Frazier Life Sciences XI, L.P. (FLS XI), raising over $987 million, surpassing its target of $800 million. This fourth venture fund will continue focusing on biopharmaceuticals and innovative therapeutics through company creation and early-stage investments. Under the leadership of experienced partners, FLS XI follows the $617 million FLS X from 2020, adding to the firm’s total capital raised to over $3.1 billion. Frazier Life Sciences has supported numerous companies, including Phathom Pharmaceuticals (NASDAQ: PHAT) and Arcutis Biotherapeutics (NASDAQ: ARQT).
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the grant of 18,900 restricted stock units and options for 48,900 shares of its common stock to four new hires. These awards were authorized by the Compensation Committee and are part of the 2022 Inducement Plan, effective March 11, 2022. The restricted stock units vest over four years, while the stock options have a ten-year term with an exercise price of $16.85 per share, equal to the closing price on the grant date. This move is aligned with Nasdaq Listing Rule 5635(c)(4).
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a biopharmaceutical company specializing in immuno-dermatology, will participate in the upcoming Cowen 42nd Annual Health Care Conference on March 7, 2022. The fireside chat is scheduled for 2:50 p.m. EST. Interested investors can access the webcast via the Events section of the company's website.
Arcutis focuses on innovative treatments for immune-mediated dermatological diseases, currently advancing multiple clinical programs and has one NDA under FDA review.
Arcutis Biotherapeutics (ARQT) announced FDA acceptance of the NDA for roflumilast cream for plaque psoriasis treatment. The company completed enrollment for a pivotal Phase 3 trial in seborrheic dermatitis and is currently enrolling trials for atopic dermatitis and psoriasis. Arcutis secured $225 million in non-dilutive financing, extending its cash runway into 2024, supported by $388.6 million in cash and equivalents. Despite a net loss of $71.3 million for Q4 2021 and $206.4 million for the full year, Arcutis aims for a pivotal year with potential product launches in 2022.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the completion of subject enrollment in its STRATUM Phase 3 trial for topical roflumilast foam, targeting seborrheic dermatitis, a condition affecting over 10 million Americans. The trial aims to evaluate the safety and efficacy of roflumilast foam, with top-line results expected by mid-2022 and a potential NDA submission in the first half of 2023. This therapeutic approach represents a significant advancement, as current treatments are inadequate, especially for hard-to-treat areas like the scalp and face.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced a $225 million term loan from SLR Capital Partners aimed at strengthening its financial position ahead of a pivotal 2022. This financing, which extends the cash runway into 2024, supports the anticipated FDA approval and launch of topical roflumilast cream for plaque psoriasis and upcoming clinical data readouts for various dermatological conditions. The loan features a five-year interest-only period and is secured by the company’s assets.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the FDA's acceptance of its new drug application (NDA) for roflumilast cream, targeting adults and adolescents with psoriasis. The PDUFA target action date is set for July 29, 2022. The NDA is backed by positive results from pivotal Phase 3 studies, DERMIS 1 and 2, which demonstrated significant efficacy compared to placebo. If approved, roflumilast cream will be the first topical PDE4 inhibitor for psoriasis, aiming to improve treatment options for patients.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the appointment of Mas Matsuda as General Counsel and Corporate Secretary, succeeding Keith Klein, who is retiring after 30 years in the industry. Matsuda, previously at Halozyme, brings over 20 years of legal expertise, which will aid in Arcutis' focus on growing its pipeline of therapies for immune-mediated skin diseases. Notably, the company is preparing for the potential approval of topical roflumilast cream for psoriasis and ongoing pivotal studies across multiple dermatological conditions.
Arcutis Biotherapeutics (Nasdaq: ARQT) presented data at the RAD Conference indicating their proprietary cream vehicle for atopic dermatitis demonstrated similar moisturizing effects compared to a commercial ceramide moisturizer. The study involved 40 patients with mild eczema, showing no significant changes in transepidermal water loss (TEWL), suggesting both products were non-damaging. Patient assessments highlighted comparable improvements in skin conditions like dryness and irritation. The study supports ongoing investigations into roflumilast cream for treating atopic dermatitis.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced its participation in the Guggenheim 3rd Annual Neuro/Immunology Conference on November 16, 2021, at 1:00 p.m. EST. This late-stage biopharmaceutical company focuses on innovations in immuno-dermatology to improve treatment for patients with immune-mediated dermatological diseases. The conference will be virtual, and webcasts can be accessed on the company's website. Arcutis aims to revolutionize care for conditions like plaque psoriasis and atopic dermatitis, with key data readouts expected by the end of 2022.